在2023年9月14日，加州大学旧金山分校和MAPS公司等机构的研究人员在医学顶刊《Nature Medicine》上发布了题为"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial"的研究论文。这个研究探讨了MDMA是否可以作为治疗PTSD的有效药物，其结果令人鼓舞。PTSD：背景和因素 首...
抗抑郁药物五羟色胺再摄取抑制剂(SSRI)是FDA批准的用于治疗PTSD的一线治疗药物,但是有近一半的患者对该药物无反应。 2023年9月14日,加州大学旧金山分校和MAPS的研究人员在国际顶尖医学期刊Nature Medicine上发表了题为:MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 t...
研究共纳入104名PTSD患者,至研究结束时,接受MDMA-AT治疗的患者中,86.5%得到临床获益,71%不再符合PTSD标准,效果优于安慰剂对照组。 这是MDMA治疗研究中多种族参与者比例最高的研究。 研究共包括104名PTSD患者,随机分配接受MDMA-AT(n=54)或安慰剂辅助治疗(n=51),共有94名参与者完成了试验,9名参与者终止治疗(MD...
2.Mitchell, J.M., Bogenschutz, M., Lilienstein, A. et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27, 1025–1033 (2021). https://doi.org/10.1038/s41591-021-01336-3 3.https://www.businessinsider.com/psychedelics-...
"67% of them lost their PTSD diagnosis." MAPS PBC plans to submit its latest results for publication, and, later this year, ask the Food and Drug Administration to approve MDMA as a prescription medication, in combination with therapy. In response to potential backlash over the use of ...
a head-to-head comparison of MDMA-assisted therapy with SSRIs for PTSD would be needed. Although the present study tested the effects of MDMA using a model in which both treatment groups received supportive therapy, participants who received MDMA and supportive therapy (d = 2.1) had greate...
Three sessions of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy over 3 months significantly improved symptoms of post‐traumatic stress disorder (PTSD) compared with placebo plus therapy in a Phase 3 trial. MDMA‐assisted therapy also resulted in improvement in a measure of functional ...
This multi-site, randomized, double-blind, confirmatory phase 3 study evaluated the efficacy and safety of 3,4-methylenedioxymethamphetamine-assisted therapy (MDMA-AT) versus placebo with identical therapy in participants with moderate to severe post-tra
FDA Accepts New Drug Application for MDMA-Assisted Therapy for PTSD. Pharmacy Times. February 13, 2024. Accessed June 4, 2024. https://www.pharmacytimes.com/view/fda-accepts-new-drug-application-for-mdma-assisted-therapy-for-ptsd 2. Jacobs A. FDA Panel Rejects MDMA-Aided Therapy for PTSD...
[9]Lewis CR, Tafur J, Spencer S, Green JM, Harrison C, Kelmendi B, Rabin DM, Yehuda R, Yazar-Klosinski B, Cahn BR. Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD. Front Psychiatry...